ArticleBritish journal of cancer2023

Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers.

Ioannis Ntafoulis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.